Celadon Pharmaceuticals PLC (CEL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Celadon Pharmaceuticals PLC (CEL) has a cash flow conversion efficiency ratio of -0.525x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.29 Million ≈ $-156.59 USD) by net assets (GBX2.45 Million ≈ $298.46 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Celadon Pharmaceuticals PLC market cap and net worth for the company's overall valuation and market capitalisation.
Celadon Pharmaceuticals PLC - Cash Flow Conversion Efficiency Trend (2019–2023)
This chart illustrates how Celadon Pharmaceuticals PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Celadon Pharmaceuticals PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Celadon Pharmaceuticals PLC ranked by their cash flow conversion efficiency. See Celadon Pharmaceuticals PLC cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Frontier IP Group Plc
LSE:FIPP
|
-0.044x |
|
Nexus Infrastructure plc
LSE:NEXS
|
-0.031x |
|
FOXO Technologies Inc.
NYSE MKT:FOXO
|
-0.060x |
|
CAP-XX Limited
LSE:CPX
|
-0.190x |
|
Slate Grocery REIT
TO:SGR-U
|
0.025x |
|
Viaplay Group AB Series A
ST:VPLAY-A
|
0.037x |
|
Induction Healthcare Group PLC
LSE:INHC
|
-0.052x |
|
Tern Plc
LSE:TERN
|
-0.090x |
Annual Cash Flow Conversion Efficiency for Celadon Pharmaceuticals PLC (2019–2023)
The table below shows the annual cash flow conversion efficiency of Celadon Pharmaceuticals PLC from 2019 to 2023. View Celadon Pharmaceuticals PLC stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | GBX3.18 Million ≈ $387.04 |
GBX-5.97 Million ≈ $-726.62 |
-1.877x | -116.58% |
| 2022-12-31 | GBX7.04 Million ≈ $856.20 |
GBX-6.10 Million ≈ $-742.19 |
-0.867x | -76.53% |
| 2021-12-31 | GBX6.41 Million ≈ $780.00 |
GBX-3.15 Million ≈ $-383.02 |
-0.491x | +37.31% |
| 2020-12-31 | GBX99.03K ≈ $12.05 |
GBX-77.57K ≈ $-9.44 |
-0.783x | -4386.83% |
| 2019-12-31 | GBX-113.47K ≈ $-13.81 |
GBX1.98K ≈ $0.24 |
-0.017x | -- |
About Celadon Pharmaceuticals PLC
Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products. Its products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.